In recent years, considerable bipartisan Congressional action, leadership from both Democratic and Republican administrations, and broad-based multistakeholder collaborations have focused on improving the tools and regulatory processes at the Food and Drug Administration (FDA), other government agencies, and public-private collaborations to support more efficient and timely development of…
The October issue of Health Affairs includes articles on topics ranging from emergency department (ED) readiness to serve children to global inequities in access to…
Medicare’s persistent underinvestment in primary care services has contributed to stresses in US health care; this underscores the important role Medicare can play in creating…
Little is known about hospital indemnity insurance in the Medicare context; in this article, we propose an initial research agenda and identify four potential strategies…
A recent decision in Oregon signals that federal courts may be wary of interfering with efforts by state legislatures to establish regulatory processes that consider…
No child should be disenrolled from, or not enrolled in, the coverage to which they are entitled due to faulty systems and incorrect procedures veiled…
The answer to improving disability data collection is not to retain the current ACS-6 but to adopt tested questions that use a scaled response and…
There is no universally endorsed standard for defining disability status.
Ahead of upcoming federal alignment changes, states should work with their long-term care delivery system partners to explore how innovative linkages of existing policies and…
Join Health Affairs Thursday, October 17, 2024, for a virtual event featuring a conversation between Health Affairs Senior Editor Dr. Margaret Winchester and Dr. Purva…
If CMS cannot persuade GRAIL of the importance of randomization and using cancer death as the outcome, then it should cancel the study.
